 |
|
|
| |
Once-Weekly Islatravir Plus Lenacapavir Maintains HIV-1 Suppression Through 96 Weeks: Phase 2 Study
|
| |
| |
CROI 2026 Feb 22-25 Denver
Amy E. Colson1*, Gordon E. Crofoot2, Peter J. Ruane3, Moti N. Ramgopal4, Alexandra W. Dretler5, Ronald G. Nahass6, Gary I. Sinclair7, Mezgebe Berhe8, Shan-Yu Liu9, Shaline Madera9, Hadas Dvory-Sobol9, Cyril Llamoso10, Elizabeth G. Rhee10, Devi Sengupta9, Joseph Eron11
1Community Resource Initiative, Boston, Mass, USA; 2he Crofoot Research Center, Houston, Texas, USA; 3Ruane Clinical Research, Los Angeles, California, USA; 4Midway Immunology & Research Center, Fort Pierce, FL, USA; 5Metro Infectious Disease Consultants, Decatur, Georgia, USA; 6ID Care, Hillsborough, NY, USA; 7Prism Health North Texas, Dallas, Tx, USA; 8North Texas Infectius Disease Consultants, Dallas, Tex, USA; 9Gilead Sciences, Foster City, Calif, US; 10Merck & Co, Rhwy, NJ, USA; 11 Univ. of North Carolina, Chapel Hill, No Carolina, USA.
|
| |
|
|
|
|
|
